A BUPRENORPHINE TRANSDERMAL PATCH FOR USE IN THE TREATMENT OF PAIN FOR A DOSING INTERVAL OF AT LEAST 4 DAYS

摘要

A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.